Skip to main content

SUNLENCA (Gilead Sciences Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
139 (255 working days)
Active ingredients
lenacapavir sodium
Registration type

SUNLENCA, in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Registration process

Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available

Help us improve the Therapeutic Goods Administration site